Insights from Fc receptor biology: A route to improved antibody reagents

mAbs

Volumn 4, Issue 3, 2012, Pages 291-293

  Woof, Jenny M ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY;

ALLERGY; ANAPHYLAXIS; ANTIGEN BINDING; AUTOIMMUNE DISEASE; LIPID RAFT; MEMBRANE BINDING; MOLECULAR BIOLOGY; NEUTROPHIL; NONHUMAN; RECEPTOR BINDING; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNITY, HUMORAL; RECEPTORS, FC; RESEARCH;

EID: 84860908610     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.20100     Document Type: Review

References (34)

1. Moore GL, Chen H, Karki S, Lazar GA. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2010; 2:181-9; PMID:20150767; http://dx.doi.org/10.4161/mabs.2.2.11158.
2. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 2006; 103:4005-10; PMID:16537476; http://dx.doi.org/10.1073/pnas.0508123103.
3. Oganesyan V, Damschroder MM, Leach W, Wu H, Dall'Acqua WF. Structural characterization of a mutated, ADCC-enhanced human Fc fragment. Mol Immunol 2008; 45:1872-82; PMID:18078997; http://dx.doi.org/10.1016/j.molimm.2007.10.042.
4. Lu Y, Vernes JM, Chiang N, Ou Q, Ding J, Adams C, et al. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays. J Immunol Methods 2011; 365:132-41; PMID:21185301; http://dx.doi.org/10.1016/j.jim.2010.12.014.
5. Horton HM, Bernett MJ, Peipp M, Pong E, Karki S, Chu SY, et al. Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies. Blood 2010; 116:3004-12; PMID:20616215; http://dx.doi.org/10.1182/ blood-2010-01-265280.
6. An Z, Forrest G, Moore R, Cukan M, Haytko P, Huang L, et al. IgG2m4, an engineered antibody isotype with reduced Fc function. MAbs 2009; 1:572-9; PMID:20073128; http://dx.doi.org/10.4161/mabs.1.6.10185.
7. Kaufman A, Herold KC. Anti-CD3 mAbs for treatment of type 1 diabetes. Diabetes Metab Res Rev 2009; 25:302-6; PMID:19319985; http://dx.doi.org/10.1002/ dmrr.933.
8. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009; 8:226-34; PMID:19247305; http://dx.doi.org/10.1038/nrd2804.
9. Vaccaro C, Zhou J, Ober RJ, Ward ES. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 2005; 23:1283-8; PMID:16186811; http://dx.doi.org/10.1038/nbt1143.
10. Oganesyan V, Damschroder MM, Woods RM, Cook KE, Wu H, Dall'acqua WF. Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol 2009; 46:1750-5; PMID:19250681; http://dx.doi.org/10. 1016/j.molimm.2009.01.026.
11. Kubagawa H, Oka S, Kubagawa Y, Torii I, Takayama E, Kang DW, et al. Identity of the elusive IgM Fc receptor (FcmuR) in humans. J Exp Med 2009; 206:2779-93; PMID:19858324; http://dx.doi.org/10.1084/jem.20091107.
12. Chen K, Xu W, Wilson M, He B, Miller NW, Bengtén E, et al. Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils. Nat Immunol 2009; 10:889-98; PMID:19561614; http://dx.doi.org/10.1038/ni.1748.
13. Jönsson F, Mancardi DA, Zhao W, Kita Y, Iannascoli B, Khun H, et al. Human FcγRIIA induces anaphylactic and allergic reactions. Blood 2012; 119:2533-44; PMID:22138510; http://dx.doi.org/10.1182/blood-2011-07-367334.
14. Lu J, Ellsworth JL, Hamacher N, Oak SW, Sun PD. Crystal structure of Fcγ receptor I and its implication in high affinity γ-immunoglobulin binding. J Biol Chem 2011; 286:40608-13; PMID:21965667; http://dx.doi.org/10. 1074/jbc.M111.257550.
15. Ramsland PA, Farrugia W, Bradford TM, Sardjono CT, Esparon S, Trist HM, et al. Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes. J Immunol 2011; 187:3208-17; PMID:21856937; http://dx.doi.org/10.4049/jimmunol.1101467.
16. Holdom MD, Davies AM, Nettleship JE, Bagby SC, Dhaliwal B, Girardi E, et al. Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor FcεRI. Nat Struct Mol Biol 2011; 18:571-6; PMID:21516097; http://dx.doi.org/10.1038/nsmb.2044.
17. Mizushima T, Yagi H, Takemoto E, Shibata-Koyama M, Isoda Y, Iida S, et al. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells 2011; 16:1071-80; PMID:22023369; http://dx.doi.org/10.1111/j.1365-2443.2011.01552.x.
18. Carroll-Portillo A, Spendier K, Pfeiffer J, Griffiths G, Li H, Lidke KA, et al. Formation of a mast cell synapse: Fc ε RI membrane dynamics upon binding mobile or immobilized ligands on surfaces. J Immunol 2010; 184:1328-38; PMID:20042583; http://dx.doi.org/10.4049/jimmunol.0903071.
19. Hubert P, Heitzmann A, Viel S, Nicolas A, Sastre-Garau X, Oppezzo P, et al. Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy. Cancer Res 2011; 71:5134-43; PMID:21697279; http://dx.doi.org/10.1158/0008-5472.CAN-10-4222.
20. Beekman JM, Bakema JE, van der Poel CE, van der Linden JA, van de Winkel JG, Leusen JH. Protein 4.1G binds to a unique motif within the Fc γ RI cytoplasmic tail. Mol Immunol 2008; 45:2069-75; PMID:18023480; http://dx.doi.org/10.1016/j.molimm.2007.10.024.
21. Gibson AW, Li X, Wu J, Baskin JG, Raman C, Edberg JC, et al. Serine phosphorylation of FcγRI cytoplasmic domain directs lipid raft localization and interaction with protein 4.1G. J Leukoc Biol 2012; 91:97-103; PMID:22003208; http://dx.doi.org/10.1189/jlb.0711368.
22. Bournazos S, Hart SP, Chamberlain LH, Glennie MJ, Dransfield I. Association of FcgammaRIIa (CD32a) with lipid rafts regulates ligand binding activity. J Immunol 2009; 182:8026-36; PMID:19494328; http://dx.doi.org/10.4049/ jimmunol.0900107.
23. Bakema JE, Ganzevles SH, Fluitsma DM, Schilham MW, Beelen RH, Valerius T, et al. Targeting FcαRI on polymorphonuclear cells induces tumor cell killing through autophagy. J Immunol 2011; 187:726-32; PMID:21653835; http://dx.doi.org/10.4049/jimmunol.1002581.
24. Lohse S, Derer S, Beyer T, Klausz K, Peipp M, Leusen JH, et al. Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing. J Immunol 2011; 186:3770-8; PMID:21317397; http://dx.doi.org/10.4049/jimmunol.1003082.
25. Balu S, Reljic R, Lewis MJ, Pleass RJ, McIntosh R, van Kooten C, et al. A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol 2011; 186:3113-9; PMID:21257971; http://dx.doi.org/10.4049/jimmunol.1003189.
26. Bakema JE, van Egmond M. Immunoglobulin A: A next generation of therapeutic antibodies? MAbs 2011; 3:352-61; PMID:21691145; http://dx.doi.org/ 10.4161/mabs.3.4.16092.
27. Woof JM, Russell MW. Structure and function relationships in IgA. Mucosal Immunol 2011; 4:590-7; PMID:21937984; http://dx.doi.org/10.1038/mi.2011.39.
28. Beyer T, Lohse S, Berger S, Peipp M, Valerius T, Dechant M. Serum-free production and purification of chimeric IgA antibodies. J Immunol Methods 2009; 346:26-37; PMID:19427867; http://dx.doi.org/10.1016/j.jim.2009.05.002.
29. Karagiannis SN, Josephs DH, Karagiannis P, Gilbert AE, Saul L, Rudman SM, et al. Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. Cancer Immunol Immunother 2011; PMID:22139135; http://dx.doi.org/10.1007/s00262-011-1162-8.
30. Call ME, Chou JJ. A view into the blind spot: solution NMR provides new insights into signal transduction across the lipid bilayer. Structure 2010; 18:1559-69; PMID:21134635; http://dx.doi.org/10.1016/j.str.2010.11.002.
31. Yahav T, Maimon T, Grossman E, Dahan I, Medalia O. Cryo-electron tomography: gaining insight into cellular processes by structural approaches. Curr Opin Struct Biol 2011; 21:670-7; PMID:21813274; http://dx.doi.org/10.1016/ j.sbi.2011.07.004.
32. Spendier K, Lidke KA, Lidke DS, Thomas JL. Single-particle tracking of immunoglobulin E receptors (FcεRI) in micron-sized clusters and receptor patches. FEBS Lett 2012; 586:416-21; PMID:22265688; http://dx.doi.org/10.1016/j. febslet.2012.01.013.
33. Zarnitsyna VI, Zhu C. Adhesion frequency assay for in situ kinetics analysis of cross-junctional molecular interactions at the cell-cell interface. J Vis Exp 2011; 3519; PMID:22083316.
34. Shashidharamurthy R, Zhang F, Amano A, Kamat A, Panchanathan R, Ezekwudo D, et al. Dynamics of the interaction of human IgG subtype immune complexes with cells expressing R and H allelic forms of a low-affinity Fcgamma receptor CD32A. J Immunol 2009; 183:8216-24; PMID:20007585; http://dx.doi.org/10.4049/ jimmunol.0902550.